Therapeutic Compositions Directed To Host Mirna For The Treatment Of Sars-Cov-2 (Covid-19) Infection
AssigneesThe Regents of the University of Colorado, a body corporate, United States of America as represented by the Administrator of NASA
InventorsAnushree Chatterjee, Afshin Beheshti, Sylvain Vincent Costes, Thomas R. Aunins, Prashant Nagpal
Life of this patent
Estimating the term…
Abstract
The inventive technology generally relates to systems, methods, and compositions for the treatment of viral infections, as well as novel use of antisense technology to rationally design antiviral compositions that can be applied to clinical cases and human infections. In one preferred aspect, the inventive technology includes methods, and compositions to treat COVID-19 in humans through the targeted inhibition of host-derived miRNAs.
Claims17
1-10. (canceled)
A pharmaceutical composition comprising at least one antisense FASTmer complementary to a target sequence of a microRNA (miRNA) expressed by said subject, and wherein said antisense oligomer bind to, and inhibits said miRNA, and a pharmaceutically acceptable carrier.
19-26. (canceled)
A pharmaceutical composition comprising at least one antisense peptide nucleic acid (PNA) FASTmer directed to a target sequence of microRNA-2392 (miRINA-2392), and a pharmaceutically acceptable carrier.
A composition comprising an antisense peptide nucleic acid (PNA) FASTmer directed to a target sequence of microRNA-2392 (miRINA-2392), wherein said antisense PNA FASTmer comprises a PNA having sequence according to SEQ ID NOs. 1, or 2, or a combination of the same.
Dependencies are inferred from the claim text.